PURPOSE OF REVIEW: Genetic variants in GBA1 and LRRK2 genes are the commonest genetic risk factor for Parkinson disease (PD); however, the preclinical profile of GBA1 and LRRK2 variant carriers who will develop PD is unclear. This review aims to highlight the more sensitive markers that can stratify PD risk in non-manifesting GBA1 and LRRK2 variant carriers.
RECENT FINDINGS: Several case-control and a few longitudinal studies evaluated clinical, biochemical, and neuroimaging markers within cohorts of non-manifesting carriers of GBA1 and LRRK2 variants. Despite similar levels of penetrance of PD in GBA1 and LRRK2 variant carriers (10-30%), these individuals have distinct preclinical profiles. GBA1 variant carriers at higher risk of PD can present with prodromal symptoms suggestive of PD (hyposmia), display increased α-synuclein levels in peripheral blood mononuclear cells, and show dopamine transporter abnormalities. LRRK2 variant carriers at higher risk of PD might show subtle motor abnormalities, but no prodromal symptoms, higher exposure to some environmental factors (non-steroid anti-inflammatory drugs), and peripheral inflammatory profile. This information will help clinicians tailor appropriate screening tests and counseling and facilitate researchers in the development of predictive markers, disease-modifying treatments, and selection of healthy individuals who might benefit from preventive interventions.
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1091-1097
[PMID:
31221723]
Hum Mol Genet. 2023 Feb 19;32(5):773-789
[PMID:
36130205]
Mov Disord. 2021 May;36(5):1267-1272
[PMID:
33617695]
Neurology. 2020 Dec 15;95(24):e3428-e3437
[PMID:
32999056]
Ann Clin Transl Neurol. 2019 May 09;6(6):1024-1032
[PMID:
31211166]
Brain. 2020 Oct 1;143(10):3077-3088
[PMID:
32830221]
Ann Neurol. 2016 Nov;80(5):674-685
[PMID:
27717005]
Mov Disord. 2022 May;37(5):1004-1015
[PMID:
35049090]
Eur J Neurol. 2020 Jul;27(7):1285-1295
[PMID:
32170820]
Mov Disord. 2016 Oct;31(10):1527-1534
[PMID:
27430880]
Mov Disord. 2021 Mar;36(3):774-779
[PMID:
33278043]
Front Neurosci. 2020 Mar 10;14:193
[PMID:
32210756]
Cereb Cortex. 2020 May 14;30(5):2867-2878
[PMID:
31813991]
Mov Disord. 2016 Jun;31(6):906-14
[PMID:
27041685]
Brain. 2019 Jan 1;143(1):234-248
[PMID:
31755958]
Brain Topogr. 2018 Nov;31(6):1029-1036
[PMID:
29846835]
Mov Disord. 2012 Apr;27(4):526-32
[PMID:
22344629]
J Neurol. 2021 Apr;268(4):1517-1525
[PMID:
33388928]
J Parkinsons Dis. 2021;11(2):559-568
[PMID:
33492243]
JAMA Neurol. 2015 Feb;72(2):201-8
[PMID:
25506732]
Ann Neurol. 2011 Jan;69(1):193-7
[PMID:
21280089]
Brain. 2022 Oct 21;145(10):3472-3487
[PMID:
35551349]
Sci Rep. 2020 Jun 9;10(1):9329
[PMID:
32518334]
Mov Disord. 2018 Jul;33(6):966-973
[PMID:
29603409]
Mol Neurodegener. 2022 Aug 17;17(1):52
[PMID:
35978378]
NPJ Parkinsons Dis. 2021 Nov 26;7(1):104
[PMID:
34836969]
Neurology. 2020 Aug 25;95(8):e1008-e1016
[PMID:
32591474]
Lancet Neurol. 2016 Nov;15(12):1257-1272
[PMID:
27751556]
Front Mol Neurosci. 2018 Feb 15;11:43
[PMID:
29527153]
Ann Neurol. 2020 Apr;87(4):652-657
[PMID:
32030791]
Mov Disord. 2022 Jul;37(7):1375-1393
[PMID:
35521899]
Mov Disord. 2022 Aug;37(8):1767-1772
[PMID:
35733392]
Neurobiol Aging. 2017 Oct;58:239.e1-239.e7
[PMID:
28728889]
Mov Disord. 2017 May;32(5):726-738
[PMID:
28370517]
Brain. 2009 Jul;132(Pt 7):1783-94
[PMID:
19286695]
Cells. 2019 Apr 19;8(4):
[PMID:
31010158]
Mov Disord. 2022 Feb;37(2):416-421
[PMID:
34741486]
Mov Disord. 2009 Oct 15;24(13):1998-2001
[PMID:
19735093]
NPJ Parkinsons Dis. 2020 Jul 9;6:15
[PMID:
32665974]
JAMA Neurol. 2018 Jan 1;75(1):9-10
[PMID:
29131880]
Mov Disord. 2021 Jun;36(6):1451-1455
[PMID:
33570220]
Mov Disord. 2020 Oct;35(10):1727-1730
[PMID:
33068466]
Neurology. 2022 Aug 16;99(7 Suppl 1):10-18
[PMID:
35970585]
N Engl J Med. 2004 Nov 4;351(19):1972-7
[PMID:
15525722]
NPJ Parkinsons Dis. 2022 Mar 3;8(1):20
[PMID:
35241697]
NPJ Genom Med. 2021 Jan 5;6(1):2
[PMID:
33402667]
Mov Disord. 2022 Jan;37(1):190-195
[PMID:
34550621]
Transl Neurodegener. 2022 Apr 8;11(1):21
[PMID:
35395825]
Mov Disord. 2020 Dec;35(12):2201-2210
[PMID:
32853481]
Mov Disord. 2020 Nov;35(11):2106-2111
[PMID:
32658388]
Mov Disord. 2020 Oct;35(10):1755-1764
[PMID:
32662532]
Mov Disord. 2020 Oct;35(10):1854-1858
[PMID:
32875616]
Mov Disord. 2019 Sep;34(9):1365-1373
[PMID:
31251436]
Mov Disord. 2015 Jun;30(7):981-6
[PMID:
25809001]
Eur Neurol. 2016;76(1-2):19-21
[PMID:
27344356]
Mov Disord. 2013 Dec;28(14):1966-71
[PMID:
24243757]
Ann Neurol. 2019 Apr;85(4):593-599
[PMID:
30761591]
Mov Disord. 2021 Aug;36(8):1997-1998
[PMID:
34409693]
Front Neurol. 2022 Aug 12;13:971252
[PMID:
36034282]
Parkinsonism Relat Disord. 2022 May;98:21-26
[PMID:
35421781]
JAMA. 2021 Sep 14;326(10):926-939
[PMID:
34519802]
JAMA Neurol. 2015 Jan;72(1):100-5
[PMID:
25401511]
J Parkinsons Dis. 2020;10(3):1123-1132
[PMID:
32310186]
Neurosci Lett. 2017 Jan 1;636:70-76
[PMID:
27780739]
Mov Disord. 2018 Jul;33(6):960-965
[PMID:
29665080]
Brain Struct Funct. 2017 Apr;222(3):1207-1218
[PMID:
27401793]
Mov Disord. 2022 Jun;37(6):1202-1210
[PMID:
35262230]
Front Neurol. 2021 Feb 26;12:635958
[PMID:
33716938]
Lancet Neurol. 2008 Jul;7(7):583-90
[PMID:
18539534]
Mov Disord. 2020 May;35(5):774-780
[PMID:
31958187]
Metabolism. 1986 Apr;35(4):343-8
[PMID:
3959904]
Ann Neurol. 2021 Jul;90(1):76-88
[PMID:
33938021]
Lancet Neurol. 2020 Jan;19(1):71-80
[PMID:
31678032]
Transl Neurodegener. 2020 May 6;9(1):15
[PMID:
32375873]
Mov Disord. 2016 Jun;31(6):889-97
[PMID:
26917005]
Mov Disord. 2020 Jan;35(1):134-141
[PMID:
31505072]
Neurology. 2007 Nov 6;69(19):1836-42
[PMID:
17984451]
Neurology. 2015 Jul 7;85(1):89-95
[PMID:
26062626]
Parkinsonism Relat Disord. 2021 Oct;91:1-8
[PMID:
34425330]
PLoS One. 2018 Aug 20;13(8):e0201964
[PMID:
30125297]
JAMA Neurol. 2018 Mar 1;75(3):312-319
[PMID:
29309488]
J Parkinsons Dis. 2021;11(3):1285-1296
[PMID:
33998549]
Mov Disord. 2019 Oct;34(10):1464-1470
[PMID:
31412427]
Sleep. 2017 Aug 1;40(8):
[PMID:
28472425]
